Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06250283 · ClinicalTrials.gov registry record · NA
Resveratrol for the Prevention of Bone Loss in Postmenopausal Women
A NA study of Low Bone Mass, sponsored by University of Delaware.
- Completed
- Registry status
- NA
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT06250283 is a NA study of Low Bone Mass that has completed, run by University of Delaware. The registered enrollment target is 52 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06250283, a NA study of Low Bone Mass, has completed, sponsored by University of Delaware.
- COMPLETED
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine whether daily supplementation of resveratrol would improve bone health in postmenopausal women.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Resveratrol
Study Locations (1)
Delaware
- University of Delaware - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2024-02-02 |
| Est. Completion | 2026-01-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06250283
The ClinicalTrials.gov registry entry for NCT06250283 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Delaware, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Low Bone Mass appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06250283 reports 1 study location spanning 1 distinct geographic area - top geographies include Delaware.
Frequently Asked Questions
What is clinical trial NCT06250283 about?
NCT06250283 is a clinical study titled "Resveratrol for the Prevention of Bone Loss in Postmenopausal Women". The purpose of this study is to examine whether daily supplementation of resveratrol would improve bone health in postmenopausal women.
What is the current status of trial NCT06250283?
This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2024-02-02. Estimated completion is 2026-01-30.
What conditions does trial NCT06250283 study?
This clinical trial studies the following conditions: Low Bone Mass.
What interventions are being tested in trial NCT06250283?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Resveratrol (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06250283?
This trial is sponsored by University of Delaware, which has 106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06250283 being conducted?
This trial has 1 study location across Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.